Physician profile
Shimon Menachem Harary
NPI 1801030192
$734,575.84
in general payments reported to CMS, 2019-2025
38 companies · $104K in 2025
The $104K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $112K · 2021: $79K · 2022: $177K · 2023: $105K · 2024: $69K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $244K · Consulting Fee: $16K · Travel and Lodging: $11K · Food and Beverage: $4,045 · Honoraria: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $244,014.25 |
| Consulting Fee | $16,050.00 |
| Travel and Lodging | $10,816.12 |
| Food and Beverage | $4,045.24 |
| Honoraria | $2,415.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $452,934.59 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135,868.77 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $111,355.02 | 2019-2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $18,343.34 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $7,837.69 | 2020-2024 | Freestyle Libre 3, Eterna, Freestyle Libre |
| Medtronic Minimed, INC. | $4,789.08 | 2019-2020 | |
| Medtronic, INC. | $1,401.79 | 2021-2025 | Minimed 780g |
| Amgen INC. | $409.65 | 2019-2025 | Tepezza, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $192.78 | 2019-2025 | |
| Abbvie INC. | $169.18 | 2019-2024 | |
| Cequr Corporation | $164.61 | 2024-2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $122.47 | 2019-2021 | |
| Corcept Therapeutics | $117.38 | 2024-2025 | Korlym |
| Horizon Therapeutics Plc | $99.88 | 2021-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $94.69 | 2019-2024 | |
| Insulet Corporation | $57.75 | 2019-2025 | Omnipod |
| Sequel Med Tech, LLC | $44.12 | 2024-2025 | Twiist |
| Recordati_rare_diseases_inc. | $37.90 | 2022-2025 | Isturisa |
| Pfizer INC. | $33.11 | 2022-2025 | |
| Radius Health, INC. | $30.87 | 2023-2025 | Tymlos |
| Nevro Corp. | $30.11 | 2023 | Senza |
| Ibsa Pharma INC. | $29.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $28.53 | 2021-2022 | |
| Optos, INC. | $23.28 | 2021 | |
| Antares Pharma, INC. | $23.07 | 2022 | |
| Verity Pharmaceuticals INC. | $22.68 | 2025 | Tlando |
| Novartis Pharmaceuticals Corporation | $22.08 | 2024 | |
| Abiomed | $21.05 | 2024 | Impella |
| Eusa Pharma (US) LLC | $20.15 | 2022 | |
| Azurity Pharmaceuticals, INC. | $19.82 | 2023 | Triptodur |
| Alexion Pharmaceuticals, INC. | $18.96 | 2024 | Strensiq |
| Amarin Pharma, INC. | $18.18 | 2021 | |
| Grt US Holding, INC. | $15.75 | 2022 | |
| Shire North American Group INC | $14.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.46 | 2019 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shimon Harary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.